Recode Therapeutics
Clinical trials sponsored by Recode Therapeutics, explained in plain language.
-
Inhaled mRNA therapy shows promise for rare lung disease
Disease control CompletedThis early-phase trial tested an inhaled mRNA therapy called RCT1100 in 14 adults with primary ciliary dyskinesia (PCD) caused by a specific genetic mutation (DNAI1). The goal was to see if the treatment could improve mucociliary clearance — the lungs' ability to clear mucus and …
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental mRNA inhalation therapy targets rare lung disease
Disease control CompletedThis early-phase study tests an inhaled mRNA therapy called RCT1100 in 7 adults with primary ciliary dyskinesia caused by DNAI1 gene mutations. The goal is to see if the treatment is safe and can help restore ciliary function in the lungs. It is a small, open-label trial focused …
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Rare lung disease study aims to uncover key health markers
Knowledge-focused CompletedThis completed study observed 31 adults with primary ciliary dyskinesia (PCD), a rare lung condition, along with healthy volunteers. Researchers measured lung function, mucus clearance, and lung structure using tests like spirometry and CT scans. The goal was to better understand…
Sponsor: ReCode Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC